Luckey et al., 2025(The Lancet): An international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial was conducted. The study evaluated the efficacy and safety of zoliflodacin versus ceftriaxone plus azithromycin in patients aged 12 years and older with clinical suspicion of uncomplicated urogenital gonorrhoea. Eligible participants were randomly assigned (2:1) […]
Zoliflodacin show promise against drug resistant infection urogenital gonorrhoea
